search
Back to results

European Deep Brain Stimulation (DBS) Depression Study

Primary Purpose

Depressive Disorder, Major

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Deep Brain Stimulation
Deep Brain Stimulation
Sponsored by
Abbott Medical Devices
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depressive Disorder, Major focused on measuring Depressive Disorder, Unipolar, Implantable Stimulation Electrodes

Eligibility Criteria

21 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Men and women (non-pregnant) age is 21-70 years;
  • Diagnosed with non-psychotic major depressive disorder, single or recurrent episode by DSM-IV-TR criteria derived from the MINI;
  • First episode onset before age 45;
  • Current episode > 12 month duration;
  • In the current episode: Documented resistance to a minimum of 4 adequate depression treatments from at least 3 different categories;
  • In adult lifetime (>21 year of age) have experience a period of wellness as defined by DSM IV criteria;
  • MADRS score ≥22 at 2 separate baseline visits, rated by 2 separate psychiatrists;
  • GAF score <50;
  • Mini-mental state examination (MMSE) score >24;
  • No change in current antidepressant medication regimen or medication free for at least 4 weeks prior to study entry;
  • Able to give informed consent in accordance with institutional policies;

Exclusion Criteria:

  • A diagnosis of bipolar I or bipolar II disorder by DSM-IV-TR criteria, derived from the MINI;
  • Meets criteria for borderline or antisocial personality disorder in the last 12 months by DSM-IV-TR criteria, derived from the Cluster B Personality Disorders Sections 301.7 - 301.83, preferably screened via SCID-II at Baseline visit (optional);
  • In the current depressive episode, has been diagnosed with General Anxiety Disorder (GAD) - as defined by the DSM-IV-TR, and GAD is the primary diagnosis;

Sites / Locations

  • CHU Pasteur
  • Hôpital La Pitié Salpêtrière
  • Hadassah-Hebrew University Medical Center
  • King's College London
  • National Hospital for Neurology and Neurosurgery - UCL

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Group B

Group A

Arm Description

Low Programming

Normal Programming

Outcomes

Primary Outcome Measures

Percentage of change from mean baseline values in MADRS score

Secondary Outcome Measures

Percentage of change from baseline value of HDRS

Full Information

First Posted
April 4, 2011
Last Updated
May 18, 2015
Sponsor
Abbott Medical Devices
search

1. Study Identification

Unique Protocol Identification Number
NCT01331330
Brief Title
European Deep Brain Stimulation (DBS) Depression Study
Official Title
A Clinical Evaluation of Different Device Parameters for the Management of Patients With Treatment Resistant Major Depressive Disorder, Single or Recurrent Episode, With Deep Brain Stimulation
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
January 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott Medical Devices

4. Oversight

5. Study Description

Brief Summary
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for TR-MDD, single or recurrent episode on mood as measured by the MADRS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depressive Disorder, Major
Keywords
Depressive Disorder, Unipolar, Implantable Stimulation Electrodes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group B
Arm Type
Active Comparator
Arm Description
Low Programming
Arm Title
Group A
Arm Type
Experimental
Arm Description
Normal Programming
Intervention Type
Device
Intervention Name(s)
Deep Brain Stimulation
Other Intervention Name(s)
Libra Deep Brain Stimulation System (St. Jude Medical Neuromodulation Division)
Intervention Description
Normal DBS Programming
Intervention Type
Device
Intervention Name(s)
Deep Brain Stimulation
Other Intervention Name(s)
Libra Deep Brain Stimulation System(St. Jude Medical Neuromodulation Division)
Intervention Description
Low Programming
Primary Outcome Measure Information:
Title
Percentage of change from mean baseline values in MADRS score
Time Frame
6 Months
Secondary Outcome Measure Information:
Title
Percentage of change from baseline value of HDRS
Time Frame
3, 6, 9, and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and women (non-pregnant) age is 21-70 years; Diagnosed with non-psychotic major depressive disorder, single or recurrent episode by DSM-IV-TR criteria derived from the MINI; First episode onset before age 45; Current episode > 12 month duration; In the current episode: Documented resistance to a minimum of 4 adequate depression treatments from at least 3 different categories; In adult lifetime (>21 year of age) have experience a period of wellness as defined by DSM IV criteria; MADRS score ≥22 at 2 separate baseline visits, rated by 2 separate psychiatrists; GAF score <50; Mini-mental state examination (MMSE) score >24; No change in current antidepressant medication regimen or medication free for at least 4 weeks prior to study entry; Able to give informed consent in accordance with institutional policies; Exclusion Criteria: A diagnosis of bipolar I or bipolar II disorder by DSM-IV-TR criteria, derived from the MINI; Meets criteria for borderline or antisocial personality disorder in the last 12 months by DSM-IV-TR criteria, derived from the Cluster B Personality Disorders Sections 301.7 - 301.83, preferably screened via SCID-II at Baseline visit (optional); In the current depressive episode, has been diagnosed with General Anxiety Disorder (GAD) - as defined by the DSM-IV-TR, and GAD is the primary diagnosis;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
DeLea Peichel
Organizational Affiliation
Abbott Medical Devices
Official's Role
Study Director
Facility Information:
Facility Name
CHU Pasteur
City
Nice
ZIP/Postal Code
06002
Country
France
Facility Name
Hôpital La Pitié Salpêtrière
City
Paris
ZIP/Postal Code
75651
Country
France
Facility Name
Hadassah-Hebrew University Medical Center
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Facility Name
King's College London
City
London
ZIP/Postal Code
SE5 9RS
Country
United Kingdom
Facility Name
National Hospital for Neurology and Neurosurgery - UCL
City
London
ZIP/Postal Code
WC1N 3
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

European Deep Brain Stimulation (DBS) Depression Study

We'll reach out to this number within 24 hrs